The Implantable Miniature Telescope for macular degeneration

Department of Ophthalmology, University of Minnesota, Stillwater, USA.
Current Opinion in Ophthalmology (Impact Factor: 2.5). 03/2006; 17(1):94-8. DOI: 10.1097/
Source: PubMed


The function is described of the Implantable Miniature Telescope, which is completing clinical development for bilateral end-stage macular degeneration, and 6-month results of the Phase II/III IMT002 prospective, multicenter study are presented. Multispecialty patient management and implications of the study's findings are discussed.
No medical treatments are currently available for bilateral end-stage age-related macular degeneration (atrophic or disciform scar age-related macular degeneration). The visual prosthetic device discussed in this update is implanted in the posterior chamber to reduce the impact of the scotomata on the patient's central vision. The goal of treatment is to improve the patient's ability to perform everyday activities and participate in roles and hobbies that impact their quality of life. Patients implanted with the device experienced clinically significant gains in visual acuity and quality of life at 6 months. In total, 89% gained two or more lines of best-corrected near or distance visual acuity. The device was generally safe and well tolerated. The surgical technique is important to minimize surgically related reduction in endothelial cell density.
This age-related macular degeneration visual prosthesis has been shown to improve visual acuity and quality of life for the bilateral end-stage age-related macular degeneration patient population that at present has no other acceptable options. Endothelial cell density from baseline to 6 and 12 months after device implantation was reduced due to trauma from the surgical procedure, but was compatible with a healthy cornea. Meticulous surgical technique and a comprehensive, multispecialty approach to preoperative and postoperative patient management are essential for successful outcomes.

6 Reads
  • Source
    • "Tear fluid contains many biomarkers that closely correlate to levels found in blood, such as glucose, cholersterol, sodium, and potassium [2]. Thus, through integrating biological sensors and telemetry, an active contact lens could provide health professionals with a new tool for research studies and for diagnosing diseases, without the need for lab chemistry or needles [3]. Fig. 1 shows a conceptual diagram of an active contact lens. "
    [Show abstract] [Hide abstract]
    ABSTRACT: We present progress toward a wirelessly-powered active contact lens comprised of a transparent polymer substrate, loop antenna, power harvesting IC, and micro-LED. The fully integrated radio power harvesting and power management system was fabricated in a 0.13 μm CMOS process with a total die area of 0.2 mm<sup>2</sup>. It utilizes a small on-chip capacitor for energy storage to light up a micro-LED pixel. We have demonstrated wireless power transfer at 10 cm distance using the custom IC and on-lens antenna.
    IEEE Transactions on Biomedical Circuits and Systems 01/2011; 4(6-4):454 - 461. DOI:10.1109/TBCAS.2010.2081989 · 2.48 Impact Factor
  • Source
    • "The results were similar at 2 years with a mean improvement of 3.2 lines in distance visual acuity and 2.9 lines in near visual acuity. The main limitation and FDA concern regarding this interesting intraocular device is the endothelial cell loss due to trauma from the implantation procedure (20% at 3 months, 25.3% at 12 months and 27.8% at 2 years).49,50 "
    [Show abstract] [Hide abstract]
    ABSTRACT: This essay reviews the experimental treatments and new imaging modalities that are currently being explored by investigators to help treat patients with age-related macular degeneration (AMD). Interpretative essay. Literature review and interpretation. Experimental treatments to preserve vision in patients with exudative AMD include blocking vascular endothelial growth factor (VEGF), binding VEGF, and modulating the VEGF receptors. Investigators are also attempting to block signal transduction with receptor tyrosine kinase inhibitors. Experimental treatments for non-exudative AMD include agents that target inflammation, oxidative stress, and implement immune-modulation. The effectiveness of these newer pharmacologic agents has the potential to grow exponentially when used in combination with new and improved imaging modalities that can help identify disease earlier and follow treatment response more precisely. With a better understanding, at the genetic and molecular level, of AMD and the development of superior imaging modalities, investigators are able to offer treatment options that may offer unprecedented visual gains while reducing the need for repetitive treatments.
    Clinical ophthalmology (Auckland, N.Z.) 02/2009; 3(1):167-74.
  • [Show abstract] [Hide abstract]
    ABSTRACT: To describe the surgical procedure for placement of an implantable telescope prosthesis for end-stage age-related macular degeneration. As part of a phase 2/3 clinical trial for patients with bilateral, irreversible age-related macular degeneration, the optimal procedure for monocular placement of the telescope prosthesis was determined. Because of the unique configuration of the telescope prosthesis, proper wound construction, anterior chamber management, and device insertion after phacoemulsification are critical for successful surgery. A unique surgical technique ensures appropriate placement of the telescope prosthesis, while reducing surgical trauma to the corneal endothelium.
    Archives of Ophthalmology 09/2007; 125(8):1118-21. DOI:10.1001/archopht.125.8.1118 · 4.40 Impact Factor
Show more

Similar Publications